Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YMN-136 Vaccine in Colorectal Cancer Liver Metastasis
NCT07409805Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2026
- Primary completion
- Jun 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YMN-136 in colorectal cancer (CRC), sponsored by West China Hospital of Sichuan University. Primary endpoints: Incidence of Treatment-Related Adverse Events at 24 months and Maximum Tolerated Dose at 24 months. Started May 2026; status: recruiting.
02
Drugs
YMN-136
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07409805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07409805.